Clinical trial NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
Official title: A Natural History Study in Patients With Genetically Confirmed Diagnosis of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Autosomal Dominant Optic Atrophy
Optic Atrophy, Autosomal Dominant
Optic Atrophies, Hereditary
Kjer Optic Atrophy
Lead sponsor: PYC Therapeutics
Sponsor class: INDUSTRY
First posted: 2023-11-18
Enrollment: 1
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will consist of approximately 40 participants (80 eyes) with a genetically confirmed OPA1 mutation.

Brief summary: The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

Detailed description: This is a multi-center, longitudinal, prospective, observational natural history study of patients with confirmed OPA1 mutation (haploinsufficiency) associated ADOA. The study will be conducted at up to 10 sites across the United States, Australia and Europe.

Each participant's medical record will be reviewed for historical information, and clinical data will be recorded in a secure database. Natural history data will be collected prospectively and will include ophthalmic exams, imaging studies and electrophysiological testing. Assessments will be conducted as described in this protocol approximately every 3 months in the first year and every 6 months in the second year of the study after each participant's baseline visit

Eligibility criteria: Inclusion Criteria:

* Participants and/or their parent(s)/guardian(s) must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. Assent, where appropriate, will be obtained according to institutional guidelines.
* Males and females, 8 years of age and above.
* Have a clinical diagnosis of OPA1 mutation (haploinsufficiency) associated ADOA.
* No other ocular pathology.
* Patients with best-corrected visual acuity (BCVA) of between 20/40 (70 Early Treatment of Diabetic Retinopathy Study \[ETDRS\] letters) and 20/160 (39-43 ETDRS letters)
* Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
* For sites performing the Detection of apoptosis in retinal cells (DARC) procedure, and in volunteers ≥ 12 years only:

  1. Female volunteers must:

     I. Be of non-child-bearing potential at least 6 weeks before the screening visit or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause), or

     II. If of childbearing potential, must:
     * Have a negative pregnancy test at the screening visit and prior to each administration of ANX776, and
     * Agree not to attempt to become pregnant or donate ova from signing the consent form until at least 30 days after the last dose of ANX776, and
     * Agree to use adequate contraception (defined as the use of a condom by the male partner combined with the use of a highly effective method of contraception from one month prior to screening until at least 30 days after the last dose of ANX776, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.
  2. Male volunteers must:

     * Agree not to donate sperm from signing the consent form until at least 90 days after the last dose of ANX776, and
     * If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as the use of a condom combined with the use of a highly effective method of contraception) from signing the consent form until at least 90 days after the last dose of study drug.

Exclusion Criteria:

* Participant has a known allergy to ANX776 or any of its excipients.
* Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study, which includes but is not limited to, infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues, or any other medical condition that may put the participant at risk due to study procedures. Note: comorbidities relevant to the pathogenesis of OPA1 associated ADOA (including hearing loss, peripheral neuropathy, myopathy, and ataxia) are acceptable.
* Have mutations in genes that cause ADOA, other than OPA1 (for example in case of dominant negative ADOA) and ADOA Plus.
* Within 3 months prior to Baseline (Visit 2), have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries \[2 or more\]) or any other ocular surgery.
* Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmic evaluation or photography, as assessed by the Investigator.
* Have used any investigational drug or device within 90 days or 5 estimated half-lives of Visit 2, whichever is longer, or plan to participate in another study of a drug or device during the study period. Participation in observational trials is allowable based on Investigator discretion and consultation with the Medical Monitor. It is assumed that the observational trial evaluations would not interfere with participation in this study.
* Have received any prior cell or gene therapy for a retinal condition.
* Have a recent history (\<6 months) of or current excessive recreational drug or alcohol use, in the opinion of the Investigator. Note: excessive alcohol use is defined as regular consumption of \> 10 standard drinks per week or \> 4 standard drinks per day, where 1 standard drink is defined as 10 grams of pure alcohol.
* Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

Primary outcomes:
measure: Best-corrected High Contrast Visual Acuity (HCVA)
timeFrame: Baseline through Year 2
measure: Low Contrast Visual Acuity (LCVA)
timeFrame: Screening through Year 2
measure: Contrast Sensitivity
timeFrame: Baseline through Year 2
measure: Color Vision
timeFrame: Baseline through Year 2
measure: Retinal Thickness
timeFrame: Baseline through Year 2
measure: Ellipsoid Zone (EZ) Volume
timeFrame: Baseline through Year 2
measure: Ellipsoid Zone (EZ) Area
timeFrame: Baseline through Year 2
measure: Visual Field Sensitivity
timeFrame: Baseline through Year 2
measure: Multifocal Visual Evoked Potential (mfVEP)
timeFrame: Baseline through Year 2
measure: Pregnancy Test
timeFrame: Baseline
measure: DARC (Detection of Apoptosing Retinal Cells)
timeFrame: Baseline through Year 2
measure: Flavoprotein Fluorescence (FPF)
timeFrame: Baseline through Year 2
measure: Retinal Abnormalities
timeFrame: Baseline through Year 2
measure: Adverse Events (AEs)
timeFrame: Screening through Year 2
measure: Genomic Analysis for Study Eligibility
timeFrame: Screening
measure: Vital signs
timeFrame: Baseline through Year 2
Secondary outcomes:
measure: To determine the outcome measures that are associated with ADOA disease progression.
timeFrame: Baseline through Year 2
Other outcomes:
measure: To evaluate the safety of ANX776 in patients ≥ 12 years.
timeFrame: Baseline through Year 2
Locations:
city: Miami
country: United States
facility: Bascom Palmer Eye Institute
state: Florida
city: Seattle
country: United States
facility: University of Washington
state: Washington
city: Sydney
country: Australia
facility: Sydney Eye Hospital
state: New South Wales
city: Graz
country: Austria
facility: Medical University of Graz
state: Styria
city: Rennes
country: France
facility: CHU de Rennes
state: Brittany
city: Hanover
country: Germany
facility: Medizinische Hochschule Hannover
state: Lower Saxony
city: Amsterdam
country: Netherlands
facility: Amsterdam University Medical Centers
Study officials:
affiliation: PYC Therapeutics
name: Sreenivasu Mudumba, PhD
role: STUDY_CHAIR
References: